Status:
COMPLETED
Regorafenib in Metastatic Colorectal Cancer : a Cohort Study in the Real-life Setting
Lead Sponsor:
Centre Oscar Lambret
Collaborating Sponsors:
Bayer
Conditions:
Metastatic Colorectal Cancer
Eligibility:
All Genders
18+ years
Brief Summary
This is a largest cohort study aimed to estimate the overall survival of patients been treated with regorafenib for metastatic colorectal cancer (mCRC) within the frame of a french compassionate progr...
Detailed Description
Regorafenib (REG) is a multi-kinase inhibitor with survival benefits in patients with pretreated mCRC, as demonstrated in the phase III CORRECT study. As a result, REG has been made available for medi...
Eligibility Criteria
Inclusion
- Inclusion criteria :
- Patient ≥ 18 years old
- With a colorectal cancer metastatic histologically proven
- Have met the criteria defined in the monograph ATU (Temporary Authorization for Use) validated by French Health Authorities and for which the request for access to treatment has been validated, that is in patients with mCRC as used in clinical practice for mCRC who have been previously treated with, or are not considered candidates for, available therapies.
- Patients who received at least one dose on REG
- Exclusion criteria :
- Opposed to the study
- Patient does not meet the inclusion criteria
- Patient deprived of liberty or under guardianship
Exclusion
Key Trial Info
Start Date :
February 1 2014
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 1 2014
Estimated Enrollment :
704 Patients enrolled
Trial Details
Trial ID
NCT02310477
Start Date
February 1 2014
End Date
December 1 2014
Last Update
August 9 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Centre Oscar Lambret
Lille, France, 59020